Cipla's Breakthrough: USFDA Greenlights Generic Cancer Drug

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles. Equivalent to Bristol Myers Squibb's Abraxane, it treats various cancers and is set to launch this fiscal year.

Cipla, a major player in the pharmaceutical industry, announced on Friday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic cancer treatment drug.

The drug, paclitaxel protein-bound particles for injectable suspension, has been cleared following the company's Abbreviated New Drug Application (ANDA). This medication is a generic version of Bristol Myers Squibb's Abraxane and comes in a 100 mg/vial, single-dose format.

Intended for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, and metastatic adenocarcinoma of the pancreas, Cipla plans to launch this product in the US during the current fiscal year's first half. The announcement resulted in Cipla's shares trading 2.73% higher at Rs 1,454.90 on the Bombay Stock Exchange (BSE).

(With inputs from agencies.)